A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

Bristol-Myers Squibb200 enrolled

Overview

The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs. One drug combination is stavudine (d4T) plus didanosine (ddI) plus Crixivan. The other combination is Retrovir (AZT) plus Epivir (3TC) plus Crixivan.

100 patients will be randomized to receive Zerit (Stavudine) + Videx (Didanosine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir (Lamivudine) + Crixivan (Indinavir). Patients will be treated for 48 weeks.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

200

Conditions

HIV Infections

Interventions

Indinavir sulfateDRUG

LamivudineDRUG

StavudineDRUG

ZidovudineDRUG

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: * Documented HIV infection. * CD4 cell count of 200 - 700 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: AIDS defining condition within 1 month of study entry. Prior Medication: Excluded: Patients with any history of antiretroviral therapy treatment.

Locations (13)

East Bay AIDS Clinic

Berkeley, California, United States

Harbor UCLA Med Ctr / Division of Immunology / N-24

Torrance, California, United States

Anderson Clinical Research

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.